Pharmaceutical composition for prevention or treatment of blood cancer comprising surf4 inhibitor

Abstract

One aspect relates to a pharmaceutical composition for the prevention or treatment of blood cancer, comprising a surfeit locus protein 4 (SURF4) inhibitor. The composition according to one aspect inhibits SURF4 to increase the expression of pJNK and decrease the expression of pERK and pAKT, and thus apoptosis of blood cancer cells is increased, thereby exhibiting an effect of preventing or treating blood cancers. In addition, by administering the composition according to one aspect together with an existing anticancer agent, a synergistic effect showing more significant apoptosis than when an existing anticancer agent was administered was confirmed, which can contribute to the blood cancer treatment market/industry.

Dependencies are inferred from the claim text.